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When Activity Requires Breaking Up: 
LEKTI Proteolytic Activation Cascade 
for Specific Proteinase Inhibition
Laetitia Furio1,2 and Alain Hovnanian1,2,3
Lymphoepithelial Kazal-type related inhibitor (LEKTI) is a multidomain 
proteinase inhibitor whose defective expression causes Netherton syndrome 
(NS). LEKTI is encoded by SPINK5, which is also a susceptibility gene for atopic 
disease. In this issue, Fortugno et al. report an elegant and thorough study of the 
LEKTI proteolytic activation process in which they identify the precise nature of 
the cleavage sites used and the bioactive fragments generated. They propose 
a proteolytic activation model in human skin and confirm differential inhib-
ition of kallikrein (KLK) 5, 7, and 14 by the major physiological LEKTI fragments. 
They show that these bioactive fragments inhibit KLK-mediated proteolysis of 
desmoglein 1 (DSG1) and suggest a fine-tuned inhibition process controlling 
target serine proteinase (SP) activity.
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Proteases and their inhibitors as 
essential actors in skin desquamation 
and inflammation: loss of control in nS
Proteinases and regulation of their activ-
ity play important roles in many aspects 
of skin biology and function, such 
as epidermal differentiation, barrier 
formation and shedding, inflamma-
tion, immune responses, host defense, 
wound healing, and hair formation 
(Meyer-Hoffert, 2009; Ovaere et al., 
2009). Human tissue kallikreins (KLKs) 
are secreted SPs with (chymo)trypsin-
like specificity that comprise 15 mem-
bers, several of which are expressed 
in the skin (Borgoño et al., 2007). In 
particular, KLK5, KLK7, and KLK14 are 
involved in the desquamation of super-
ficial layers of corneocytes by degrad-
ing corneodesmosomal components. 
They also activate protease-activated 
receptor-2 (PAR-2), resulting in the 
production of inflammatory cyto-
kines (Brattsand et al., 2005; Hachem 
et al., 2006; Komatsu et al., 2005). 
Protease inhibitors are essential actors 
in the control of protease activity. In 
the epidermis, they include LEKTI 
(or LEKTI-1), LEKTI-2, SPINK6, skin- 
derived anti leukoprotease (SKALP/
elafin), secre tory leukocyte protease 
inhibitor, bikunin, hurpin, other SP 
inhibitors (SERPINS), and cystatins 
(Brattsand et al., 2009; Magert et al., 
2005; Meyer-Hoffert, 2009; Zeeuwen, 
2004).
The importance of a tight control of 
protease activity has been dramatical-
ly illustrated in NS, a rare and severe 
genetic skin disease in which loss of 
balance between LEKTI, a SP inhibitor, 
and its target proteinases leads to a pro-
found skin barrier defect with severe 
inflammatory and allergic manifesta-
tions (Chavanas et al., 2000; Bitoun 
et al., 2002; Deraison et al., 2007; 
Descargues et al., 2006). Studies in NS 
patients and in murine models have 
shown that LEKTI deficiency results in 
unopposed KLK5 activity, leading to 
a dual mechanism (Descargues et al., 
2005; Hewett et al., 2005; Yang et al., 
2004). KLK5 degrades DSG1, causing 
abnormal stratum corneum detach-
ment, leading to a severe skin barrier 
defect that favors increased allergen 
penetration in the skin. In parallel, 
unrestrained KLK5 activity triggers an 
autonomous inflammatory cascade by 
activating PAR-2 signaling, resulting 
in the production of major pro-inflam-
matory molecules and pro–T helper 
type 2 (Th2) cytokines such as thymic 
stromal lymphopoietin (TSLP). This 
specific KLK5–PAR2–TSLP pathway, in 
addition to producing thymus and acti-
vation-regulated chemokine and mac-
rophage-derived chemokine, IL-1, and 
tumor necrosis factor-α, contributes to 
the creation of a pro-inflammatory and 
pro-allergic Th2 microenvironment 
that predisposes NS patients to severe 
skin allergy, asthma, and food allergy 
(Bonnart et al., 2010; Briot et al., 2009, 
2010; Fontao et al., 2011).
LeKtI isoform structure, transport,  
and secretion
LEKTI cDNA was cloned by Magert et 
al. from D1 and D6 fragments isolated 
from blood ultrafiltrates (Magert et al., 
1999). LEKTI is encoded by SPINK5, 
which maps to chromosome 5q33.1 
within a gene family cluster includ-
ing SPINK6 and SPINK9, encoding 
the single-domain inhibitors SPINK6 
and LEKTI-2, respectively (Brattsand 
et al., 2009; Meyer-Hoffert, 2009; 
Meyer-Hoffert et al., 2010). SPINK5 
consists of 33 exons spread over 61 
kb, encoding 15 domains preceded 
by a peptide signal and interspaced by 
linker regions. The LEKTI protein pri-
mary structure shows that each domain 
shares a Kazal-type related motif found 
in SP inhibitors. In fact, only domains 2 
and 15 contain the classic Kazal motif 
defined by the presence of 6-cysteine 
residues with precise spacing; other 
domains exhibit only a 4-cysteine 
pattern. This allows the formation of 
two or three intramolecular disulfide 
bonds, resulting in a rigid reactive cen-
ter loop that mimics the substrate and 
traps the target protease. Each LEKTI 
domain, except for D1, D2, and D15, 
shares an arginine residue at position 
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P1, which predicts activity against 
trypsin-like SPs (Goettig et al., 2010). 
Linkers are arginine- and lysine-rich 
sequences that represent putative 
cleavage sites for convertin/subtilisin-
like enzymes such as furin.
Tartaglia-Polcini et al. have shown that 
LEKTI is transcribed into three different 
transcripts that differ through their car-
boxy-terminal end by alternative pro-
cessing (Tartaglia-Polcini et al., 2006). 
In addition to the 15-domain isoform 
(LEKTI-FL), SPINK5 encodes a shorter 
LEKTI isoform (LEKTI-Sh), containing 
only the first 13 domains resulting from 
differential poly adenylation. The third 
isoform is longer (LEKTI-L), carry-
ing a 30-amino-acid residue insertion 
between the thirteenth and fourteenth 
domains. All three SPINK5 alternative 
transcripts are translated into protein 
in differentiated keratinocytes, with 
LEKTI-FL being the most abundant. 
LEKTI pro-protein is rapidly cleaved 
intracellularly, generating a number of 
potentially bioactive fragments (Bitoun 
et al., 2003; Tartaglia-Polcini et al., 
2006). LEKTI is transported in lamel-
lar granules, separated from KLK5 and 
KLK7, and secreted at the granular 
and stratum corneum interface (Ishida-
Yamamoto et al., 2005).
LeKtI proteolytic activation  
cascade generates a wide variety  
of bioactive fragments
In this issue, Fortugno et al. report the 
results of a careful and exhaustive study 
of LEKTI proteolytic processing aimed 
at identifying the precise nature of the 
generated LEKTI polypeptides. The 
investigators combined antibody map-
ping, N-terminal sequencing, and spe-
cific mutagenesis of predicted cleavage 
sites to identify precisely the cleavage 
sites used and the corresponding LEKTI 
fragments generated. Pro-LEKTI proteo-
lytic processing was first studied in nor-
mal human epidermis, in differentiated 
normal human keratinocytes (NHKs), 
and in human embryonic kidney cells 
transfected with an expression plas-
mid containing the cDNA encoding for 
LEKTI-FL, LEKTI-L, and LEKTI-Sh. The 
resulting proteolytic patterns showed 
bands of 65/68, 42, 37, 30, and 23 
kDa, comparable to those reported 
by Deraison et al. (2007). The 68-kDa 
band seen with LEKTI-L corresponds to 
the extra 30-amino-acid residues of this 
isoform in linker region 13. Fragments 
of 102, 105, and 79 kDa were also 
detected in human embryonic kidney 
cells transfected with LEKTI-FL, LEKTI-L, 
and LEKTI-Sh cDNA, respectively, and 
in keratinocytes. These fragments corre-
spond to an intermediate form not seen 
in human epidermis, possibly attribut-
able to rapid processing.
Fortugno et al. (2011) subsequently 
used in silico analysis to identify poten-
tial furin cleavage sites. Numerous 
potential sites were identified, but four 
arginine residues with the highest scores 
were selected for functional studies 
(Arg355, Arg425, Arg489, and Arg625). 
Each of these sites was subsequently 
mutated to inactivate them, and the 
effect on Pro-LEKTI proteolytic process-
ing was analyzed in human embryonic 
kidney cells transfected with the mutated 
cDNA for LEKTI-FL. The 42-kDa LEKTI 
fragment was used as a prototype to vali-
date this strategy. N-terminal sequencing 
of the purified 42-kDa band showed that 
it is generated from cleavage at Arg625 
in linker region 9. Site-directed muta-
genesis of Arg625 was subsequently 
used to confirm that the 65- and 68-kDa 
fragments were generated from cleavage 
at the same site. These results identified 
Figure 1. model of LeKtI proteolytic activation cascade in human keratinocytes and inhibitory 
properties of physiological fragments. The three LEKTI isoforms—LEKTI-FL, LEKTI-L, and LEKTI-Sh—are 
represented (see text for their description). The four arginine residues used for cleavage by furin are 
indicated. The three isoforms are cleaved at Arg 355 to generate D6–D15-FL (102 kDa), D6–D15-L (105 
kDa), or D10–D13-Sh (79 kDa) fragments, which are rapidly cleaved at Arg625 to produce fragments 
D10–D15-FL (65 kDa), D10–D15-L (68 kDa), and D10–D13-Sh (42 kDa), as well as fragment D6–D9 
(37 kDa), which is common to the three isoforms. D6–D9 is subsequently cleaved into D6 (7 kDa) and 
D7–D9 (30 kDa) following cleavage at Arg 425. D7–D9 is further cleaved at Arg 489 to generate D7 (7 
kDa) and D8–D9 (23 kDa). Proteolytic processing of fragment D1–D5 was not included in this study 
and is not yet fully understood. D1 and D5 are represented as single domains because they, like D6, 
were identified from human blood ultrafiltrates (Magert et al., 1999). Additional proteolytic fragments 
derived from D2–D4 are not represented. However, there is evidence that fragments of 20, 15, 13, 11, 
and 10 kDa are generated from this fragment, the identity of which remains to be established (Deraison 
et al., 2007). Domains are color coded according to their inhibitory properties found in Fortugno et 
al. (this issue, 2011) for C-terminal fragments (D6–D9, D10–D13, D10–D15, and derived fragments). 
For N-terminal fragments (D1–D5), D1–D6 was previously shown to inhibit strongly KLK5 and KLK14 
(Borgoño et al., 2007), D5 inhibits KLK5 and KLK14 (Deraison et al., 2007), and D1 does not inhibit any 
of these KLKs. Note that, except for D6–D9, the physiological proteolytic fragments do not match 
LEKTI fragments previously investigated for inhibition studies. Pink, preferential and strong inhibition 
of KLK5 and KLK14; blue, preferential but weaker inhibition of KLK7; yellow, unknown or no inhibition 
of KLK5 or KLK7. LEKTI domains are represented as cylinders; linker regions are shown as curved black 
lines between domains. The peptide signal sequence is indicated in green at the N-terminal end of the 
molecules. K, classic Kazal-type domain (D2 and D15).
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unambiguously the 65- and 68-kDa 
fragments as being D10–D15 derived 
from LEKTI-FL and LEKTI-L, respectively, 
and the 42-kDa band as corresponding 
to D10–D13 from LEKTI-Sh.
The identity of the other 37-, 30-, 
and 23-kDa fragments was determined 
by mutating the other three potential 
furin cleavage sites with the highest 
scores (Arg355, Arg425, and Arg489 in 
linker regions 5, 6, and 7, respectively) 
in the LEKTI-FL sequence. This strategy 
allowed the investigators to confirm the 
use of these cleavage sites for proteolytic 
processing and assigned the 37-, 30-, 
and 23-kDa bands to D6–D9, D7–D9, 
and D8–D9, respectively. As stated by 
Fortugno et al. (2011), differences in the 
composition of the 31-kDa LEKTI frag-
ments proposed in Deraison et al. (2007) 
are attributable to overestimation of the 
molecular weight of the D8–D9 frag-
ment by Ahmed et al. (2001).
This study identified the furin-sensitive 
sites used during pro-LEKTI proteolytic 
processing, allowing the identification 
of the LEKTI bioactive fragments gen-
erated. Fortugno et al. (2011) propose 
the following succession of cleavages 
during the activation cascade in NHK 
(Figure 1). The full-length protein (145 
kDa) is cleaved into a D6–D15 frag-
ment (102 kDa), which is rapidly pro-
cessed to generate a D6–D9 fragment 
(37 kDa), a D10–D15 fragment (65 kDa), 
and smaller amino-terminal fragments 
not reported in this study. The D10–D15 
fragment shows no evidence of subse-
quent cleavage. By contrast, the D6–D9 
fragment undergoes further proteolysis 
to release single domains (D6 and then 
D7), as well as the corresponding three- 
(D7–D9) and two-domain (D6–D9) 
fragments. The authors conclude that in 
normal keratinocytes and human epi-
dermis, pro-LEKTI proteolytic processing 
results in the generation of a wide variety 
of LEKTI polypeptides, which comprise 
at least D6–D9, D7–D9, D8–D9, D6, 
D7, D10–D15, and D10–D13 frag-
ments, with the latter being generated 
from LEKTI-Sh, which lacks D14 and 
D15 (Figure 1).
Fortugno and colleagues mainly 
investigated the carboxy-terminal region 
of the protein, from D6 to D15. Previous 
work on physiological proteolytic pro-
cessing of the amino-terminal region 
identified LEKTI fragments of 20, 15, 
13, 11, and 10 kDa, recognized by D1–
D6 antibodies from human epidermal 
extract and conditioned medium of cul-
tured NHK (Deraison et al., 2007). The 
11- and 10-kDa bands were proposed 
to correspond to D1, D5, and/or D6 pre-
viously isolated from the serum, but the 
identity of the other bands remains to be 
determined.
KLK5 and KLK14 as major target SPs  
of LeKtI physiological fragments
Initial functional studies aimed at assess-
ing LEKTI’s inhibitory capacity were 
performed with a LEKTI full-length mol-
ecule (Mitsudo et al., 2003). Protease-
inhibition assays showed inhibition 
of the SPs trypsin, plasmin, subtilisin 
A, cathepsin G, and human neutro-
phil elastase. The cysteine proteinases 
papain or cathepsin K, L, or S were not 
inhibited. However, subsequent studies 
of rLEKTI fragments reported a differ-
ent spectrum of inhibition. Specifically, 
rLEKTI D6-D9 was shown to inhibit 
trypsin, subtilisin A, KLK5, and KLK7 
(Jayakumar et al., 2004; Schechter et al., 
2005); rLEKTI D6 inhibits trypsin, KLK5, 
and KLK7, but not subtilisin A (Egelrud 
et al., 2005; Kreutzmann et al., 2004); 
rLEKTI D9–D12 inhibits KLK5, but not 
KLK7 (Schechter et al., 2005); and rLEKTI 
D15 inhibits trypsin and plasmin, but not 
KLK5 or KLK7 (Egelrud et al., 2005). The 
LEKTI inhibitory spectrum thus seems to 
be complex and highly dependent on 
the domains considered.
Deraison et al. (2007) examined the 
inhibition profiles of proposed physi-
ological LEKTI fragments against a 
wide range of human SPs. All fragments 
tested (D5, D6, D8–D11, and D9–D15) 
inhibited KLK5, KL7, and KLK14 only. 
No inhibition was observed with the 
human SPs KLK8, cathepsin G, tryptase, 
elastase, plasmin, KLK3, and thrombin. 
D8–D11 showed the strongest inhibi-
tion properties toward KLK5 and KLK14, 
whereas KLK7 was less efficiently inhib-
ited. D5, D6, and D9–D15 were weaker 
inhibitors of KLK5, KLK7, and KLK14. 
From these studies, it appeared that the 
main target proteases of these LEKTI frag-
ments were KLK5 and KLK14 and, to a 
lesser extent, KLK7.
An exhaustive study by Borgoño et 
al. (2007) tested the inhibition potential 
of four overlapping rLEKTI multidomain 
fragments covering the entire molecule 
against multiple KLKs involved in epi-
dermal desquamation. They found that 
rLEKTI D1–D6, rLEKTI D6–D9, and 
rLEKTI D9–D12 were potent inhibitors 
of KLK5 and KLK14 and that they also 
inhibited KLK6 and KLK13 to a lesser 
extent. By contrast, rLEKTI D12–D15 
inhibited KLK5 only. This work expanded 
the spectrum of KLKs inhibited by LEKTI 
fragments to KLK6 and KLK13, and KLK6 
was shown to degrade DSG1.
Fortugno et al. (2011) assessed the 
inhibitory properties of the LEKTI physi-
ological fragments that they identified 
against KLK5, KLK7, and KLK14. They 
found D6–D9 and derived multido-
main fragments D7–D9 and D8–D9 to 
be highly efficient inhibitors of KLK5 
and KLK14 but weak inhibitors of KLK7. 
Conversely, they found D10–D15 to be a 
weak inhibitor of KLK5 and KLK14, but 
that it inhibited KLK7 more efficiently. 
Single domains (D6 and D7) showed 
weaker inhibition than corresponding 
multidomain fragments.
These results confirm the differential 
inhibitory properties of LEKTI domains. 
They also support the notion that KLK5 
and KLK14 are major targets of physi-
ological LEKTI fragments, with D6–D9 
and its derived multidomain fragments 
being much more potent KLK5 and 
KLK14 inhibitors than D10–D15. These 
results are consistent with previous work 
that identified D8–D11 as the most effec-
tive LEKTI fragment, suggesting that 
D8–D9 could account for this activity 
(Deraison et al., 2007). Fortugno et al. 
(2011) also show that KLK7 is inhibited 
to a lesser extent by D10–D15. However, 
the fact that LEKTI is degraded by KLK7 
suggests that LEKTI is not a major KLK7 
inhibitor. In addition, none of the LEKTI 
domains contains a large hydrophobic 
Phe, Try, or Tyr residue at position P1, as 






inhibition and a potential 
for new therapies.
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(Goettig et al., 2010). Nevertheless, 
LEKTI could regulate KLK7 activity 
through KLK5-mediated KLK7 activation.
From these data, it appears that the 
inhibitory capabilities of LEKTI fragments 
and LEKTI domains do not necessarily 
correlate with the number of domains 
contained in each fragment. Although 
unique domains (D6, D7) are usually 
weaker inhibitors than multidomain frag-
ments, two-domain fragments (D8–D9) 
can be as potent as four-domain frag-
ments (D6–D9). This suggests that the 
conformation of multidomain fragments 
could modify the accessibility of inhibi-
tory reactive loops and/or the binding to 
putative allosteric sites, thus influencing 
the inhibitory capacity of the fragment 
(Jayakumar et al., 2004).
What do these results tell us about LeKtI 
biological function?
These studies identify the nature of physio-
logical LEKTI fragments derived from D6 
to D15, crucial information for assessing 
their biological functions. They confirm 
that KLK5 and KLK14 are major target 
proteases of D6–D9 and derived domains, 
whereas fragments D10–D15 are more 
potent KLK7 inhibitors. KLK5, KLK14, 
and KLK7 play a central role in skin des-
quamation. In fact, Fortugno et al. (2011) 
showed that LEKTI fragments derived 
from D6–D9 had a differential capability 
to inhibit KLK14- versus KLK5-mediated 
DSG1 degradation in vitro. Further stud-
ies may explore the inhibitory capacities 
of these physio logical fragments toward 
other epidermal KLKs and SPs.
These results are consistent with the 
biological cascades described in NS 
patients and in mouse models of NS 
(Briot et al., 2009, 2010; Descargues et 
al., 2005). In these models, unopposed 
KLK5 activity initiates an autonomous 
cascade, leading to stratum corneum 
detachment and skin barrier defect, 
inflammation, allergy, filaggrin degrada-
tion, and lipid abnormalities. Notably, 
proteases not inhibited by LEKTI directly, 
such as elastase 2, also play important 
roles in NS, as shown by a transgenic 
mouse model that overexpresses elastase 
2 (Bonnart et al., 2010).
The different inhibition properties 
displayed by LEKTI fragments probably 
represent an advantage in addressing 
the diversity of exogenous and/or endog-
enous target proteinases. Likewise, the 
large number of LEKTI domains would 
contribute to quickly release a signifi-
cant number of bioactive fragments at 
the site of injury. LEKTI would thus act 
as a “cluster bomb”—able to rapidly 
mobilize a significant number of bioac-
tive fragments from a single molecule.
Impact on the development of new 
treatments for nS and allergy
Understanding the physiological LEKTI 
fragments and their inhibitory properties 
has the potential to influence the design 
of new treatments for NS. In topical pro-
tein-replacement therapy, penetration of 
selected LEKTI fragments would be ham-
pered by their large molecular weight 
and would require skin delivery systems. 
Nevertheless, the profound skin barrier 
defect seen in NS could facilitate diffu-
sion through a disrupted stratum cor-
neum. Alternatively, and perhaps more 
importantly, these results confirm that 
KLK5, KLK14, and KLK7 are potential 
therapeutic targets whose specific inhi-
bition by small lead compounds might 
block unrestrained protease activity, 
leading to pharmacological inhibition of 
the pathogenic cascades.
Finally, in light of the work by Fortugno 
et al. (2011), spontaneous mutations 
abolishing or creating furin cleavage sites 
in linker regions may impact LEKTI pro-
cessing and proteolytic activation. These 
mutations could underlie more subtle SP 
deregulation in the epidermis, which may 
have a clinical impact and contribute to a 
genetic predisposition to eczema (Walley 
et al., 2001).
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Cuts by Caspase-14 Control the 
Proteolysis of Filaggrin
Leopold Eckhart1 and Erwin Tschachler1,2
Although mutations in the filaggrin gene (FLG) have been shown to be associated 
with ichthyosis vulgaris and atopic dermatitis, the function and regulation of 
filaggrin remain incompletely understood. In this issue, Hoste et al. report that 
filaggrin is directly cleaved by caspase-14. Acting in concert with other proteases, 
caspase-14 controls the breakdown of filaggrin to free amino acids and amino 
acid derivatives that contribute to the hydration and UVB absorption capacity 
of the stratum corneum. These findings identify a new layer of complexity in the 
regulation of epidermal barrier function.
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Processing of filaggrin in the epidermis
Filaggrin became a focus of dermato-
logical research when mutations in its 
gene (FLG) were found to be associ-
ated with ichthyosis vulgaris and atopic 
dermatitis (Irvine and McLean, 2006). 
Because filaggrin is expressed only in 
keratinocytes, defects in the epidermal 
barrier are now considered likely to pre-
cede immune activation and allergies in 
patients with atopic dermatitis (Irvine and 
McLean, 2006). Although the mechanism 
of FLG-associated barrier defects has not 
yet been fully elucidated, recent stud-
ies have revealed multiple interactions 
between filaggrin and other proteins that 
are critical for its physiological function.
Like other members of the S100-fused-
type protein family, filaggrin is expressed 
as a precursor protein consisting of an 
N-terminal S100 domain and a series 
of filaggrin repeats. Proteolytic process-
ing yields filaggrin monomers that are 
important in the aggregation of interme-
diate filaments during cornification of 
keratinocytes (Steinert et al., 1981). In the 
stratum corneum, complete proteolysis of 
filaggrin leads to the release of free amino 
acids that function as components of the 
natural moisturizing factor (NMF) (Scott 
and Harding, 1986) (Figure 1). Moreover, 
filaggrin-derived histidine is converted 
to urocanic acid, which protects the 
underlying layers of the skin against UVB 
radiation (Barresi et al., 2011). In addition 
to proteolysis, protein phosphorylation, 
dephosphorylation, and deimination 
control the progressive conversion of 
profilaggrin to its amino acid constituents 
(Sandilands et al., 2009). The report by 
Hoste et al. (2011, this issue) uncovers a 
novel part of the complex processing of 
filaggrin and highlights the experimental 
challenges faced by investigators studying 
biochemical processes in the outermost 
layers of the skin.
caspase-14 is a filaggrin-processing enzyme
The cysteine protease caspase-14 was 
linked to the breakdown of filaggrin 
in 2007 by Declercq and colleagues, 
who generated and characterized a 
caspase-14 knockout mouse model 
(Denecker et al., 2007). They found that 
caspase-14 deficiency was associated 
with the accumulation of incompletely 
degraded filaggrin fragments within the 
stratum corneum, a decrease in stratum 
corneum hydration, increased trans-
epidermal water loss, and sensitivity 
to UVB photodamage. In an extension 
of this work, Hoste et al. (2011) now 
provide evidence for the molecular 
mechanisms underlying the phenotype 
of caspase-14 knockout mice. The 
investigators identify direct cleavage sites 
